rongliflozin
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 21, 2022 (NCT05497674)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CCOc1ccc(Cc2cc([C@]34OC[C@]([C@@H](C)O)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1- Mol. weight
- 450.92 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314927 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05374343 | Phase 1 | May 5, 2022 | Sichuan University, Sunshine Lake Pharma Co., Ltd. |
| NCT05427682 | Phase 1 | Apr 19, 2022 | Sunshine Lake Pharma Co., Ltd. |
| NCT05497674 | Phase 1 | Feb 21, 2022 | Sunshine Lake Pharma Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sunshine Lake Pharma Co., Ltd. | For profit | 3 | 3 | 1 | 2022 |
| Sichuan University | Academic/Hospital | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1